Skip to content
Clinical Trials – home
BulgariaBack to Bulgaria

Clinical trials in Sevlievo – page 4

52 clinical trials in Sevlievo, Bulgaria across 2 research sites. Every trial is listed in the EU Clinical Trials Register and updated daily.

Sevlievo at a glance
52
clinical trials
  • Research sites2
Type of trial
Recruitment status
Quick filters

52 trials in Sevlievo

Open in trial search

Study of Anifrolumab for Adults with Moderate-to-Severe Systemic Lupus Erythematosus

InvestigationalNo placebo
Countries:BulgariaBulgaria
  • Participants:18–64 years · 65+ years
  • Substances:Anifrolumab
  • Sponsor:AstraZeneca AB

Neurodermatitis

Not recruiting

Study on the Effectiveness and Safety of Ruxolitinib Cream for Patients with Prurigo Nodularis

Investigational
Countries:BulgariaBulgaria
  • Participants:18–64 years · 65+ years
  • Substances:Ruxolitinib
  • Sponsor:Incyte Corp.

Study on the Effects of Filgotinib for Adults with Active Axial Spondyloarthritis

Registered drug
Countries:BulgariaBulgaria
  • Participants:18–64 years · 65+ years
  • Substances:Filgotinib
  • Sponsor:Alfasigma S.p.A.

Atrial fibrillation

Not recruiting

Study on Milvexian and Apixaban for Preventing Stroke in Patients with Atrial Fibrillation

Registered drug
Countries:BulgariaBulgaria
  • Participants:18–64 years · 65+ years
  • Substances:Andexanet Alfa
  • Sponsor:Janssen Cilag International

Dermatitis atopic

Not recruiting

A study testing TRIV-509 compared to placebo in adults with moderate to severe atopic dermatitis

Investigational
Countries:BulgariaBulgaria
  • Participants:18–64 years · 65+ years
  • Substances:HUMAN IGG1 BISPECIFIC MONOCLONAL ANTIBODY AGAINST KALLIKREIN-5 AND KALLIKREIN-7
  • Sponsor:Triveni Bio Inc.

Hidradenitis

Not recruiting

Study of ruxolitinib cream applied to the skin for people with hidradenitis suppurativa

Investigational
Countries:BulgariaBulgaria
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Ruxolitinib
  • Sponsor:Incyte Corp.

Study on the Safety and Immune Response of a High-Dose Influenza Vaccine in Adults Aged 60 and Over, Comparing Trivalent Influenza Vaccine with a Drug Combination

Registered drugNo placebo
Countries:BulgariaBulgaria
  • Participants:18–64 years · 65+ years · Healthy volunteers
  • Substances:A/Victoria/4897/2022 (H1N1)Pdm09-Like Strain (A/Victoria/4897/2022, Ivr-238)
  • Sponsor:Abbott Biologicals B.V.

Varicella

Not recruiting

Study on the Safety of a New Chickenpox Vaccine (GSKVX000000025896) Compared to Varicella Virus Oka/Merck Strain in Healthy Children Aged 12-15 Months

Registered drugNo placebo
Countries:BulgariaBulgaria
  • Participants:0–17 years · Healthy volunteers
  • Substances:GSKVX000000025896
  • Sponsor:GlaxoSmithKline Biologicals

Hypertriglyceridaemia

Not recruiting

Study on Plozasiran and ARO-APOC3 for Adults with Severe Hypertriglyceridemia

Investigational
Countries:BulgariaBulgaria
  • Participants:18–64 years · 65+ years
  • Substances:Synthetic Double-Stranded Sirna Oligonucleotide Directed Against Apolipoprotein C-Iii Mrna And Covalently Linked To A Ligand Containing Three N-Acetylgalactosamine Residues
  • Sponsor:Arrowhead Pharmaceuticals Inc.

Asthma

Not recruiting

Study on the Effectiveness and Safety of Budesonide, Glycopyrronium, and Formoterol Inhaler for Adults and Adolescents with Severe Asthma Not Well Controlled

Registered drug
Countries:BulgariaBulgaria
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Budesonide
  • Sponsor:AstraZeneca AB

Study on the Effectiveness and Safety of Litifilimab for Patients with Active Subacute or Chronic Cutaneous Lupus Erythematosus Resistant to Antimalarial Therapy

Investigational
Countries:BulgariaBulgaria
  • Participants:18–64 years · 65+ years
  • Substances:Litifilimab
  • Sponsor:Biogen Idec Research Limited

COVID-19

Not recruiting

Study on the Safety and Effectiveness of Nirmatrelvir and Ritonavir for Nonhospitalized Children with COVID-19 at Risk of Severe Illness

InvestigationalNo placebo
Countries:BulgariaBulgaria
  • Participants:0–17 years
  • Substances:Nirmatrelvir
  • Sponsor:Pfizer Inc.

Other cities in Bulgaria

The busiest research cities in the country

All 53 cities in Bulgaria

Clinical research in Sevlievo

What the registry says about research in the country

01 Respiratory Diseases

Innovative research focusing on respiratory viral infections and chronic conditions, evaluating new vaccines and treatments for improved patient outcomes.

  • RSV and Metapneumovirus Vaccine Studies
  • Influenza Prevention in Elderly
  • Asthma Management Therapies
  • COPD Treatment Innovations

Current trials are testing advanced vaccine formulations and novel therapeutic approaches for both acute and chronic respiratory conditions.

02 Dermatological Conditions

Comprehensive studies examining treatments for various skin disorders, from autoimmune conditions to chronic inflammatory diseases.

  • Plaque Psoriasis Treatments
  • Vitiligo Therapies
  • Atopic Dermatitis Management
  • Chronic Urticaria Solutions

Research focuses on developing targeted therapies for improved symptom management and disease control.

03 Autoimmune Disorders

Groundbreaking research into systemic autoimmune conditions, testing new biological treatments and therapeutic approaches.

  • Lupus (SLE and CLE) Studies
  • Rheumatoid Arthritis Treatments
  • Biosimilar Evaluations

Clinical trials are exploring innovative treatments to address both systemic and organ-specific manifestations of autoimmune diseases.

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.